Raymond James Trust N.A. Buys 4,324 Shares of Boston Scientific Co. (NYSE:BSX)

Raymond James Trust N.A. lifted its stake in Boston Scientific Co. (NYSE:BSX) by 25.3% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,388 shares of the medical equipment provider’s stock after buying an additional 4,324 shares during the quarter. Raymond James Trust N.A.’s holdings in Boston Scientific were worth $1,647,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. CWM LLC boosted its position in shares of Boston Scientific by 11.8% in the fourth quarter. CWM LLC now owns 28,198 shares of the medical equipment provider’s stock worth $1,630,000 after purchasing an additional 2,979 shares during the period. Russell Investments Group Ltd. boosted its holdings in Boston Scientific by 19.9% in the 4th quarter. Russell Investments Group Ltd. now owns 741,769 shares of the medical equipment provider’s stock worth $42,743,000 after buying an additional 122,979 shares during the period. Precision Wealth Strategies LLC purchased a new stake in Boston Scientific in the 4th quarter worth $956,000. Transcend Capital Advisors LLC raised its holdings in Boston Scientific by 8.9% during the fourth quarter. Transcend Capital Advisors LLC now owns 13,252 shares of the medical equipment provider’s stock valued at $766,000 after acquiring an additional 1,084 shares during the period. Finally, Eagle Wealth Strategies LLC purchased a new position in shares of Boston Scientific in the fourth quarter valued at about $541,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $77.30, for a total value of $539,785.90. Following the transaction, the executive vice president now owns 42,908 shares in the company, valued at $3,316,788.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $77.30, for a total transaction of $539,785.90. Following the transaction, the executive vice president now directly owns 42,908 shares in the company, valued at approximately $3,316,788.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 14,011 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $75.34, for a total value of $1,055,588.74. Following the sale, the executive vice president now owns 20,197 shares in the company, valued at approximately $1,521,641.98. The disclosure for this sale can be found here. In the last quarter, insiders have sold 34,960 shares of company stock valued at $2,638,984. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 0.5 %

NYSE:BSX traded down $0.41 during mid-day trading on Friday, hitting $79.17. 4,006,157 shares of the stock traded hands, compared to its average volume of 6,148,074. The company has a quick ratio of 1.14, a current ratio of 1.66 and a debt-to-equity ratio of 0.47. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $79.92. The stock has a market capitalization of $116.15 billion, a price-to-earnings ratio of 66.53, a PEG ratio of 2.49 and a beta of 0.78. The firm’s 50 day moving average is $76.59 and its two-hundred day moving average is $72.51.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.80%. The firm had revenue of $4.12 billion during the quarter, compared to the consensus estimate of $4.02 billion. During the same quarter in the previous year, the firm posted $0.53 earnings per share. The company’s revenue was up 14.5% on a year-over-year basis. On average, equities research analysts predict that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Analysts Set New Price Targets

BSX has been the topic of several recent analyst reports. Morgan Stanley lifted their target price on Boston Scientific from $79.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, July 15th. Royal Bank of Canada reissued an “outperform” rating and issued a $85.00 target price on shares of Boston Scientific in a report on Thursday, July 25th. Barclays raised their target price on shares of Boston Scientific from $78.00 to $86.00 and gave the company an “overweight” rating in a research note on Thursday. Evercore ISI increased their price objective on shares of Boston Scientific from $78.00 to $81.00 and gave the company an “outperform” rating in a report on Tuesday, July 2nd. Finally, BTIG Research lifted their target price on Boston Scientific from $80.00 to $84.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Two equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $85.24.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.